New T cell therapies for childhood cancers
NexTGen - STANFORD
This study is working on new treatments using specially designed immune cells to help kids with tough-to-treat solid tumors, like certain types of sarcomas and brain cancers, so they can have better chances of recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10625700 on NIH RePORTER |
What this research studies
This research focuses on developing next-generation T cell therapies specifically designed for treating childhood solid cancers, which current treatments often fail to cure. The approach involves advanced cellular engineering to create engineered T-cells that can effectively target and attack these cancers, overcoming challenges such as tumor heterogeneity and a hostile tumor microenvironment. By studying primary tumors to identify new targets and understanding how the tumor environment affects T-cell function, the research aims to create transformative therapies for pediatric patients. The project is structured into interconnected work-packages, initially concentrating on pediatric sarcomas and brain tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with solid tumors, particularly pediatric sarcomas and brain tumors.
Not a fit: Patients with hematologic malignancies or those whose tumors do not respond to T-cell therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide effective and durable treatment options for children suffering from solid tumors that are currently difficult to treat.
How similar studies have performed: Other research has shown promising results with engineered T-cell therapies in adult cancers, suggesting potential for success in pediatric applications as well.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Weissman, Irving L. — Stanford University
- Study coordinator: Weissman, Irving L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.